Menorrhagia nonhormonal treatment gets FDA nod

Article

After a priority review, the US Food and Drug Administration has approved Xanodyne Pharmaceuticals' formulation of tranexamic acid tablets (Lysteda) for the treatment of cyclic menorrhagia.

After a priority review, the US Food and Drug Administration has approved Xanodyne Pharmaceuticals' formulation of tranexamic acid tablets (Lysteda) for the treatment of cyclic menorrhagia. The nonhormonal product works by stabilizing a protein essential to clotting, thus reducing excessive clot breakdown in the uterus.

Approximately 10% of women of reproductive age in the United States report regular intervals of menstruation, with volume that may exceed 80 mL per cycle.

Commonly reported adverse effects of tranexamic acid tablets may include headache; sinus and nasal symptoms; pain in the back, abdomen, muscles, or joints; muscle cramps; anemia; and fatigue. Women who use oral contraceptives concurrently with tranexamic acid tablets have increased risk of blood clots, heart attack, or stroke.

US Food and Drug Administration. FDA approves Lysteda to treat heavy menstrual bleeding [press release]. November 13, 2009. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm190551.htm. Accessed November 20, 2009.

Related Videos
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit: mayo.edu.
raanan meyer, md
New data shows elinzanetant's efficacy in treating menopausal symptoms | Image Credit: uvahealth.com
Navigating vasomotor symptoms in breast cancer patients | Image Credit: menopausefoundationcanada.ca.
Fertility counseling for oncology patients | Image Credit: allhealthtv.com
Learning what women prefer in STI preventive care
Related Content
© 2024 MJH Life Sciences

All rights reserved.